THE USE OF FIXED COMBINATION OF PERINDOPRIL AND AMLODIPINE IN 2ND STAGE ARTERIAL HYPERTENSION
https://doi.org/10.15829/1560-4071-2015-9-59-64
Abstract
Aim. To evaluate efficacy and safety of combination antihypertension compound Dalneva® — combination of perindopril and amlodipine by KRKA company in treatment of patients with second stage arterial hypertension (AH).
Material and methods. Totally 36 patients included with AH of II stage (20 women, 16 men). Mean age was 56,4±2,6 y; duration of hypertension anamnesis — 8,2±1,9 y. All patients had noncontrolled AH on the previous treatment. Compliance to previously prescribed medications was low — 55,5% of patients did not take the drugs on regular basis. At the moment of study inclusion the mean systolic BP (SBP) was 166,6±28,1 mmHg, mean diastolic BP (DBP) — 90,6±11,4 mmHg. All patients were assigned the Dalneva® in various dosages: from 4/5 mg to 8/10 once per day, relating baseline condition. Efficacy of treatment was evaluated by BP level in office visits and by selfcontrol. Respectively, the correction of dosages was done. For life quality assessment, we used EQ5D and VAS before the beginning of drug intake and in 3 months of treatment. Drug tolerability was assessed with the clinical condition questionnaire CGI-I.
Results. In 3 months of therapy the mean SBP was 138,5±13,4 mmHg (p=0,001), mean DBP — 80,4±6,1 mmHg (p=0,001). Side effects, such as dry cough and peripheral edema, specific for the drug components, were not registered. The dynamics of values: by VAS — 61,2±3,8; in 3 months 72,6±3,3 (p<0,05); by EQ5D the activity, self-help at the baseline were high and did not change in Dalneva® group. CGI-I showed: 31 patients marked “significant improvement”, 2 — “very significant improvement”, 3 — minimal improvement”. The treatment by Dalneva® continued 91,6% of patients.
Conclusion. Hypotension drug Dalneva® — the fixed combination of perindopril and amlodipine — is safe and effective against AH of II stage. Once per day intake makes it comfortable and improves compliance.
References
1. The ESH-ESC Task Force for the management of arterial hypertension. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J. Hypertens 2013; 31: 1285-357.
2. Shalnova SA, Balanova YuA, Konstantinov VV, et al. Arterial hypertension: prevalence, awareness,antihypertensive pharmaceutical treatment, treatment effectiveness in Russian population. Russ J Cardiol 2006; 4: 45-50. Russian (Шальнова С. А., Баланова Ю. А., Константинов В. В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал 2006; 4: 45-50).
3. Elliott W. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens 2008; 10: 20-6.
4. Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J 2011; 32: 264-8.
5. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimes of amlodipine adding perindopril versus atenolol adding bendroflumethiazide as required in ASCOT-BPLA: а multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906.
6. Williams B, Lacy PS, Thom SM, et al. CAFE Investigators; Anglo–Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure–lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-25.
7. Bertrand ME, Ferrari R, Remme WJ, et al. Clinical Synergy of Perindopril and Calciumchannel Blocker in the Prevention of Cardiac Events and Mortality in Patients with Coronary Artery Disease. Post Hoc Analysis of the EUROPA Study. Post Hoc Analysis of the EUROPA Study. American Heart Journal. 2010;159(5): 795-802.
8. http://www.rlsnet.ru (РЕГИСТР ЛЕКАРСТВЕННЫХ СРЕДСТВ РОССИИ 2014).
9. Kobalava ZhD, Kotovskaya YV, Lukyanova EA on behalf of physicians — participants of program KONSTANTA. Combined therapy of arterial hypertension with a fixed combination of perindopril arginine/amlodipine in real clinical practice: the organization and the main results of the program KONSTANTA. Cardiology 2013; 6: 25-34. Russian (Ж. Д. Кобалава, Ю.В. Котовская, Е.А. Лукьянова от имени врачей — участников программы КОНСТАНТА/ Комбинированная терапия артериальной гипертонии с использованием фиксированной комбинации периндоприла аргинина/амлодипина в реальной клинической практике: организация и основные результаты программы КОНСТАНТА/ Кардиология 2013; 6: 25-34)
Review
For citations:
Andreicheva E.N. THE USE OF FIXED COMBINATION OF PERINDOPRIL AND AMLODIPINE IN 2ND STAGE ARTERIAL HYPERTENSION. Russian Journal of Cardiology. 2015;(9):59-64. (In Russ.) https://doi.org/10.15829/1560-4071-2015-9-59-64